Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer

BACKGROUND: There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC). METHODS: The clinical charts of 233 patients with CRPC treated with enzalutamide were...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuzuki, Shunsuke, Nakanishi, Shotaro, Tamaki, Mitsuyoshi, Oshiro, Takuma, Miki, Jun, Yamada, Hiroki, Shimomura, Tatsuya, Kimura, Takahiro, Furuta, Nozomu, Saito, Seiichi, Egawa, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486121/
https://www.ncbi.nlm.nih.gov/pubmed/34597353
http://dx.doi.org/10.1371/journal.pone.0258160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486121/
https://www.ncbi.nlm.nih.gov/pubmed/34597353
http://dx.doi.org/10.1371/journal.pone.0258160

Ejemplares similares